News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Dr. Reddy's Laboratories Ltd. (RDY)'s Q3 & 9 Months FY13 Financial Results



2/14/2013 6:18:51 AM

Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) today announced its unaudited consolidated financial results for the quarter ended December 31, 2012 under International Financial Reporting Standards (IFRS).

Key Highlights (Q3 FY13)
•Consolidated revenues for Q3 FY13 at Rs. 28.7 billion, recorded YoY growth of 23%#. Consolidated revenues for 9 months FY13 at Rs. 82.9 billion, recorded YoY growth of 26%#.? Revenues from the Global Generics segment for Q3 FY13 at Rs. 20.8 billion, recorded a YoY growth of 24%# primarily driven by North America and the Emerging market territories.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES